

NEWS RELEASE



March 19, 2019

Exclusive Distribution Agreement with Zogenix for ZX008 in Japan

Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters, Kyoto; President, Shigenobu Maekawa) announced that Nippon Shinyaku has entered into an exclusive distribution agreement in Japan for ZX008 for the treatment of Dravet syndrome and Lennox-Gastaut syndrome (LGS) with Zogenix, Inc. (Zogenix; Headquarters, CA, U.S.A.; President and CEO, Stephen J. Farr)

Zogenix is developing ZX008 internationally for the treatment of Dravet syndrome and LGS, intractable and rare childhood-onset epileptic encephalopathies. Zogenix recently completed its rolling submission of a New Drug Application to the U.S. Food & Drug Administration and the submission of a Marketing Authorization Application to the European Medicines Agency for ZX008 for the treatment of seizures associated with Dravet syndrome. Zogenix is also conducting a global Phase 3 clinical trial for ZX008 in LGS. In Japan, Zogenix is conducting Phase 3 trials for ZX008 to support submissions of new drug applications for Dravet syndrome and LGS.

At the execution of this agreement, Shigenobu Maekawa, President of Nippon Shinyaku, said, "Intractable and rare diseases is one of our most important areas of focus. We look forward to further contributing to the well-being of patients and their families, and addressing unmet medical needs in Dravet syndrome and LGS by working with Zogenix to bring ZX008 to market in Japan."

"Nippon Shinyaku's expertise and commitment to rare diseases make the company an attractive strategic distribution partner for ZX008," said Stephen J. Farr, Ph.D., President and CEO of Zogenix. "Given the current limited available treatments for Dravet syndrome and LGS in Japan, we look forward to working with Nippon Shinyaku to advance ZX008 as a potential new treatment option for patients and their families."

About Nippon Shinyaku

Our mission is to help people lead healthier and happier lives. Through creating unique medicines that will bring hope to patients and families struggling with illness, we aim to be an organization trusted by the community. Please visit our website (<http://www.nippon-shinyaku.co.jp/english/>) for products or detailed information.

About Zogenix

Zogenix is a global pharmaceutical company committed to developing and commercializing transformative therapies to improve the lives of patients and their families living with rare diseases. The company's lead candidate, ZX008 has been accepted for review by the European Medicines Agency; is awaiting an acceptance decision by the U.S. Food & Drug Administration; and is in development in Japan. For more information, visit www.zogenix.com.

Media Contact

Corporate Communications Dept., Nippon Shinyaku

TEL: +81-75-321-9103 FAX: +81-75-321-9128